INTRODUCTION
Diltiazem is a calcium ion influx inhibitor (calcium entry blocker or calcium ion antagonist). The antihypertensive, antianginal and antiarrhythmic effects of diltiazem is believed to be related to its specific cellular action of selectively inhibiting transmembrane influx of calcium in cardiac muscle, coronary arteries, and systemic arteries and in cells of the intracardiac conduction system 1 . Given orally, 90-100% of diltiazem is absorbed, but due to high first pass metabolism, bioavailability is much lower (40-60%), half life is 6-9 hours (with chronic dosages) and not cleared by hemodialysis [2] [3] .
Solid lipid microparticles (SLMs) were developed in early 1990s and have since been considered to be promising drug carrier systems 4 , especially with a view to give the incorporated active substance a sustained release profile [5] [6] . These are monolithic spherical structures with the drug distributed through out the microsphere matrix either as a molecular dispersion or as particle dispersion 7 . Solid lipids are advantageous pharmaceutical excipients being low cost, natural and biodegradable products with physiological, non toxic properties [8] [9] . The drug solubility and miscibility in melted lipid 10 , chemical and physical structure of lipid materials, and their polymorphic state determine the loading capacity of drug in the lipid particles [11] [12] .
Furthermore, the use of synthetic polymer matrix materials often goes along with detrimental effects on incorporated peptides during manufacturing of the formulations or during the erosion of the polymers after application [13] [14] . Lipid materials, e.g. triglycerides and cholesterol15, may have the potential as biocompatible and biodegradable carriers for peptides and proteins [16] [17] . In our study, we investigated the potential of physiological lipids such as monoglyceride as well as an alternative to polymers as a matrix material for controlled release devices for the diltiazem hydrochloride [18] [19] . The aim of this study was to investigate various methods of preparing lipid microparticles with respect to their suitability to encapsulate diltiazem hydrochloride [20] [21] and to characterize the resulting systems with respect to particle size 22 , modification of the lipid matrix and the in-vitro release behavior 5 .
MATERIALS AND METHODS

Materials
Diltiazem hydrochloride was received from Vipro Lifescience, (Gujarat, India), SOFTEMUL® -AS (glycerol monostearate), poly (vinyl alcohol), diethyl ether, span 60 grade from Pure Chemicals Co (Chennai, Tamil Nadu).
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Preparation methods of lipid microparticles
Solvent evaporation method widely used for the preparation of polymeric microparticles. In this method drug and polymer were dissolved in organic solvent, this mixture was kept on a magnetic stirrer. Aqueous solution of 0.5% w/v of polyvinyl alcohol containing Span 60 (0.1% w/v) as an emulsifier were stirred with the help of mechanical stirrer. Then, both the mixtures were added and stirred at 1000 rpm. Microparticles were filtered, washed with acetone and vacuum dried over night at room temperature.
Scanning electron microscopic
The surface topography of microparticles prepared by different methods was analyzed by scanning electron microscopy. The prepared microparticles were coated with gold palladium under an air atmosphere for 150 seconds to achieve a 20nm film (Coater Polaron,18mA current at 1.4 kV).The coated sample were then examined using SEM (Philips 505, Philips, Holland).
Particle size distribution
A laser light scattering technique (Mastersizer, Malvern Instruments, UK) was employed to confirm the particle size distribution of solid lipid microparticles. The dried powder samples were suspended in deionised water and sonicated for 1 min with an ultrasound probe before measurement. The compressed air system was utilized to inhibit the aggregation of dried microparticles 23 .
Differential scanning calorimetry (DSC)
Differential Scanning Calorimetry studies of Diltiazem and glycerol monostearate was carried out by heating the samples from 40 o C to 240 o C at the rate of 20 o C/min, using UNIVERSAL Q 200 V 23.5 instrument 24 .
In-vitro release study
In-vitro dissolution studies were carried out on the microparticles at the temperature of 37 o C±0.5 o C and at 100 rpm using USP Dissolution Apparatus II. Initially the dissolution studies were performed in simulated gastric fluid consisting of 0.1N (pH 1.2) hydrochloric acid without enzyme. An accurately weighed sample of microparticles was suspended in the media and dissolution study was carried out for 2 hr. At the end of the 2 hr, 400 ml of 0.1M tribasic sodium phosphate, pH was adjusted to 7.2±0.2 and added to all 6 dissolution vessels. The dissolution was continued until the microparticles were depleted of drug [25] [26] .
In-vivo release study
The oral pharmacokinetic study of diltiazem hydrochloride SLM intended for the sustained release delivery, was carried out in albino rats, which were divided in two groups each with six animals of weight 250-300 grams. The animals were fasted for 24 hr following the oral administration of 0.5 ml suspension of diltiazem hydrochloride SLM in distilled water. The plasma samples were withdrawn from retro orbital plexus region of rats at time intervals of 0, 1, 2, 4, 8, 12 and 24 hr of post administration, in the animals lightly anesthetized with ether.
Analysis of diltiazem hydrochloride from rat plasma
The plasma samples withdrawn at 0, 1, 2, 4, 8, 12 and 24 h time interval were deproteinised using acetonitrile, subjected to centrifuge at 10,000 rpm for 10 minutes at the temp of -4 o C. The clear supernatant was separated through micropipette and the drug content was analyzed using HPLC.
Pharmacokinetic parameters of diltiazem hydrochloride SLM
Oral Pharmacokinetic parameters such as maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), half life (T 1/2 ), mean residence time (MRT), were calculated using graph pad Version 5.0 software.
Stability study
Prepared formulation was stored in screw capped small glass bottles at 4±1°C, 60±5% RH and 25±1°C, 65±5% RH. Samples were analyzed for residual drug content after a period of 15, 30, 45, 60 and 90 days. Initial drug content was taken as 100 % for each formulation. The log percent residual drug content was plotted against time (t), which reflected an almost linear relationship.
Statistical analysis
Determination of corrected drug concentration: the corrected drug concentration at each time interval was calculated using the formula given below: 
RESULTS AND DISCUSSION
The method employed for the preparation of drug loaded biodegradable microparticles is the solvent evaporation technique. The present study investigated that diltiazem containing lipid microparticles can be produced in the preferred size range as a substitute to polymeric microparticles.
Selection of optimum Polymer: drug ratio
Diltiazem hydrochloride loaded microparticles were prepared using different polymer: drug ratio. Increasing the weight of polymer in a fixed volume of organic solvent resulted in an increase in mean particle size (from 71.43 ± 2.38μm to 113.52 ± 2.85μm for 1:1 to 5:1) as shown in Fig.  1 and Table  1 .
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Selection of optimum aqueous: oil phase ratio
As external dispersing phase different volumes of PVA aqueous solution were employed, resulting in different ratios between aqueous as external and oil as internal phases. Particles produced by 20:1 w/o ratio (200 ml) enabled the production of spherical microparticles with a mean diameter of 101.37 ± 2.14 μm, having the process yield of 83.24 ± 1.47% (w/w), the encapsulation efficiency of 75.13 ± 1.98% (w/w) and drug loading of 17.23 ± 1.38% (w/w). Table 3 and Fig. 3 summarizes the obtained results. 
Optimum viscosity of the external aqueous phase
Increasing viscosity of the external phase by addition of the increasing concentration of PVA led to a slight increase in the particle size 93.53±1.4 μm with 0.1% PVA to 138.85±0.89 μm with 1.0% PVA. The use of 0.5% PVA led to the formation of spherical particles with a mean diameter of 101.47±1.73 μm with the process yield of 84.34±0.64% (w/w), drug loading of 18.46±1.25% (w/w) and an encapsulation efficiency of 72.82±1.34% (w/w) which was highest among all the three concentrations of PVA (Fig. 4 and Table 4 ). 
Optimum stirring time
For a constant speed of 1000 rpm, a polymer:drug ratio of 3:1, a w/o ratio of 20:1 and a 0.5% viscosity of aqueous phase, an increase of the stirring time from 1 to 3 h resulted in reduction in microparticles size (from 115.68 ± 2.43 to 81.66 ± 2.68 μm). A 2 h stirring time was chosen because the entrapment efficiency was higher (76.08 ± 1.62%, w/w) than after 2 h (69.92 ± 1.23%, w/w) (Fig. 6 ). 
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Scanning electron microscopic studies
The spherical shape of microparticles was established by SEM. The surface analysis of empty and of drug loaded microparticles prepared by the w/o/w emulsion solvent evaporation method revealed that the microparticles were spherical with a diameter of 101.75 ± 0.82 μm and polydispersity index of as shown in Fig. 7 Differential scanning calorimetric studies
In the drug loaded microparticles of glycerol monostearate, thermogram showed a peak at 63.75 o C corresponding to the melting point of glycerol monostearate. This shift may be due to physicochemical interaction of drug and polymer as shown in fig. 8 . 
Size distribution and Size statistics
The measurement achieved by laser light scattering in order to estimate the average diameter of solid lipid microparticle of diltiazem hydrochloride evidenced the presence of some aggregates with average diameter 105.71µm, and particle size ranged between 95.76 to 115.38 µm thus presenting unimodal and narrow particle size distribution as shown in Fig. 9 .
In-vitro release studies
In-vitro Diltiazem Hydrochloride release studies from glycerol monostearate microparticles were performed for 2 h in pH 1.2 buffer (Simulated gastric fluid) and after 2 h in phosphate buffer, pH 7.2 (Simulated intestinal fluid) at temperature of 37 ± 0.5 o C. Diltiazem release from the microparticles was found to be slow and spread over extended period of 24 h 28 as shown in Fig. 10 . Percent of Diltiazem released from the microparticles was decreased with an increase in amount of coat material in the microparticle formulation (p<0.05). The increased density of the polymer matrix at higher concentrations results in an increased diffusional pathlength 26 . This may decrease the overall drug release from the polymer matrix. Furthermore, smaller microparticles are formed at a lower polymer concentration and have a large surface area exposed to dissolution medium, giving rise to faster drug release [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
Initial release stage
About 17% rapid drug release was noticed just a few minutes after suspending the microparticles in the acid solution medium and higher release rates were associated with smaller size fraction. Under the microscope, drug crystal could be observed at or near the surface of the microparticles. These surface crystals would dissolve quickly and probably account for the rapid initial release 27 . 
Release in acid after initial stage
Most of the drug release during this time period is mainly due to the initial release and could be removed with an acid wash prior to the dissolution analysis 27 . Diltiazem release from microparticles was negligible during this stage.
Release at pH 7.2
During the dissolution in the slightly neutral buffered medium pH 7.2, higher release rates were noticed for the microparticles as a result of the creation of pores and channels and probably due to swelling of polymers to some © 2011, JDDT. All Rights Reserved extent. It is evident that slopes are larger in the slightly neutral medium than in acidic one.
Kinetics of drug release
In order to investigate the release mechanism of present drug delivery system, the data obtained from in-vitro release of final optimized batch (DT-03) were fitted into equations for the zero-order, first-order, Higuchi release model and Krosmeyer Peppas model. The interpretation of data was based on the values of the resulting regression coefficients. The in-vitro drug release showed the regression coefficient values for Higuchi's model (r 2 = 0.9759) and Krosmeyer Peppas model (r 2 = 0.986) and a value of n = 0.576 represented in Fig. 11 and 12 respectively, indicating anomalous transport 29 . 
In-vivo studies
In-vivo studies were carried out in albino rats as per the established protocol and the pharmacokinetic parameters were determined.
Pharmacokinetic parameter of SLM
Pharmacokinetic analysis was carried out to determine oral parameters using comparative results from drug aqueous suspension and SLM of the diltiazem hydrochloride administered to II and III group respectively. Significantly higher Cmax values were observed for SLM formulation compared to aqueous oral suspension of same drug as shown in Fig. 13 . The highest concentration value achieved in case of drug suspension was 218.59±1.47 and the Cmax value for SLM formulation was observed as 235.85±1.29. Tmax value remained for 8 h (i.e., between 4h to 12 h time interval) in the SLM formulation indicating sustained release of drug whereas in pure drug without polymer, the highest concentration (Cmax) was observed at first time point, i.e., 2 h, this was considered as Tmax. MRT of diltiazem SLM formulation was considerably higher than the drug suspension. Half life of drug increased many fold and was found to be 12 h in SLM formulation and 2 h in drug suspension of diltiazem hydrochloride as shown in Table 8 . 
Stability studies
Diltiazem Hydrochloride microparticles in the form of lyophilized powder were stored in glass bottles at 4 ± 1 o C, 60 ± 5 % RH and 25 ± 1 o C, 75 ± 5% RH for period of 3 months and evaluated for any change in the shape and structural integrity by microscopic examination and residual drug content. At 25 ± 1 oC , agglomerates of microparticles were found after storage for three months, which may be attributed to polymer softening and fusion. Optimal storage conditions for the formulation assessed by analyzing the residual drug content after the time interval of 15, 30, 45, 60 and 90 days. The percent residual drug content was determined and found to be 99.11±0.59 at 4 ± 1 o C (Table 9 ) and 98.28±0.98 at 25 ± 1 o C (Table 10) respectively after storage for 90 days. (Fig. 14 and 15 The log % residual drug content vs. time graph was plotted for the optimized formulation in order to evaluate k (specific rate constant or degradation rate constant), t1/2 and t10% of the formulation. 
CONCLUSIONS
The present study deals with formulation and evaluation of solid lipid microparticles in the size range suitable for oral delivery by solvent evaporation technique melt dispersion technique and w/o/w emulsion solvent evaporation techniques using organic solvents. A W/O/W emulsion solvent evaporation technique was finally considered best method to prepare the SLM since it generated microspheres with spherical shape. The encapsulation efficiency of the drug into glyceryl monostearate microparticles was substantially influenced by the preparation method and the physical state of the drug to be incorporated. The w/o/w emulsion solvent evaporation techniques and the incorporation of the drug as an aqueous solution gave the best results with actual drug loadings up to 16% and an encapsulation efficiency of approximately 72%. The in-vitro release study of diltiazem hydrochloride was carried out for 24 which resulted in initial burst release of 17 % followed by slow release of 84.51 %. The release data were fitted into equations for the zero-order, first-order, Higuchi release model and Krosmeyer Peppas model. The interpretation of data was based on the values of the resulting regression coefficients. The in-vitro drug release showed the regression coefficient values for Higuchi's model (r 2 = 0.9759) and Krosmeyer Peppas model (r 2 = 0.986) and a value of n = 0.576. In-vivo studies were carried out in albino rats as per the established protocol and the pharmacokinetic parameters were determined. Cmax value for SLM formulation was observed was 235.85±1.29 where Cmax value achieved in case of drug suspension was 218.59±1.47 Tmax value
